Clinical Trial

Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome

Study acronym: RMS-OSAS
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2025 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients. This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-16.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-05-24
Trial Details
NCT Number NCT06783998
Lead Sponsor Tarsus University
Conditions Obstructive Sleep Apnea (OSAS)
Enrollment 150 participants
Start Date 2025-05-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-28